BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes
Of the $5 million, 80% comes from new investors, highlighting confidence as the Company continues to enhance its technology offerings for commercial applications.
- Of the $5 million, 80% comes from new investors, highlighting confidence as the Company continues to enhance its technology offerings for commercial applications.
- In addition, the Company also eliminated approximately $3.9 million in total existing term loans by applying such amounts to purchase approximately $3.3 million of additional convertible promissory notes and an aggregate of 231,518 common shares of BIONIK.
- The convertible notes have a maturity date of March 31, 2022 and convert into common stock at the maturity date.
- BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.